Therefore, I will focus on the most common causes of nephrotic syndrome — minimal change disease, focal segmental glomerulosclerosis (FSGS), and membranous nephropathy. Minimal Change Disease ...

Merida Biosciences has emerged from Third Rock Ventures with $121 million in first-round financing for a pipeline of drugs ...

A biotech company developing precision therapeutics that selectively eliminate pathogenic antibodies driving autoimmune and ...

Financing of Merida Biosciences was backed by Bain Capital Life Sciences, BVF Partners and Third Rock Ventures, with participation from multiple other investors.

Merida is working on a selective therapy for Graves’ disease, leveraging targeted therapies that can deplete disease-causing autoantibodies.

where doctors discovered fluid and multiple blood clots in his lungs caused by a rare kidney condition called primary membranous nephropathy. Colsaerts described the experience as “the scariest ...

IgA nephropathy, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1.

Merida is also working on a treatment for a chronic inflammatory kidney disease called primary membranous nephropathy. “At the heart of Merida is understanding the mechanisms behind antibody ...

The market for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) was valued USD 968 Million in 2017 which is anticipated to reach USD 2,020.6 Million by 2030.

The company currently has programs targeting Graves’ disease, allergy and primary membranous nephropathy, a chronic autoimmune disease that affects the kidneys. “We are driven by the ...